|
Dewpoint Therapeutics Inc, a biotechnology company pioneering condensate-modulating therapeutics, has announced the selection of a development candidate (DC) for its MYC programme.
The MYC is a master regulator of oncogenic transcription implicated across multiple high-burden cancers, yet has historically resisted direct pharmacologic control. The MYC development candidate is a first-in-class small molecule designed to disrupt MYC-driven oncogenic transcription by modulating the aberrant biomolecular condensates that organize transcriptional control in cancer cells.
“MYC has long been one of the most compelling and most elusive targets in oncology,” said Isaac Klein, MD, PhD, chief scientific officer of Dewpoint Therapeutics. “This milestone underscores the power of Dewpoint’s condensate-modulating platform to tackle foundational drivers of disease that have resisted conventional drug discovery approaches. Advancing a MYC development candidate is a significant step forward for the Company and reinforces our conviction that condensate biology can open entirely new therapeutic frontiers.”
The MYC development candidate was selected based on a comprehensive preclinical data package demonstrating potency and specificity in MYC-dependent cellular systems, favourable in vivo pharmacology, including tumour regressions in MYC-dependent models, and tolerability supportive of advancement toward IND-enabling studies. The programme is positioned to explore multiple tumour contexts in which MYC dependence is a central driver of oncogenic biology.
“What is exciting about this molecule is not just that it impacts MYC, but how it does so,” said Ann Boija, PhD, SVP head of research at Dewpoint Therapeutics. “By targeting the condensate-level organization of transcription, we are intervening at the level where MYC exerts its function. This provides a mechanistically novel and coherent framework for understanding efficacy, selectivity, and therapeutic window in MYC-driven cancers.”
It is the first MYC condensate-modulating small molecule advanced to Development Candidate. Demonstrates potent, selective inhibition of MYC-driven transcription through condensate modulation. Its preclinical data supports potential across MYC-dependent cancers.
Dewpoint is prepared to advance the MYC development candidate through IND-enabling studies while continuing to deepen its understanding of MYC condensate biology across cancer models.
Condensates are membraneless organelles that form dynamically throughout the cell through a process called phase separation. These subcellular compartments organize and concentrate molecules within cells, enabling diverse biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary, and neurological disorders. Condensate-modulating drugs (c-mods) provide novel therapeutic options for complex diseases and historically undruggable targets.
|